|
|
|
|
 |
About the Journal |
 |
|
| | Post date: 2018/04/3 | |
|
About the Journal
Iranian Journal of pharmacology and Therapeutics (IJPT) is a peer-reviewed and open access scientific journal that is published continuously by Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran. IJPT aims to give scientists the opportunity to introduce, distribute and discuss significantly improved protocols or methodologies, as well as leading edge researches that show remarkable advances in all aspects of experimental and clinical pharmacology throughout the world, employing professional, motivated and dedicated reviewers. IJPT publishes literatures that report new leading methodologies, applications, trials, therapies and remedies in the fields of Pharmacology and Therapeutics in the form of;
- Original articles
- Reviews
- Mini reviews
- Systematic reviews
- scoping reviews
- Meta analysis
- Meta Synthesis
- Case control studies
- Brief Communication
- Study protocols
- Iranian Registry of Clinical Trials (IRCTs)
- Letters to editor
- Proceedings
- Editorials
The key areas of IJPT are presented in Aims and Scope section. The authors will benefit easy submission, fast peer review and publication, reasonable and easy to follow format, online manuscript tracking, unlimited free colour figures and schemes, and other opportunities of an e-journal. Also, access to current articles, as well as several years of archived content is available free for all authors and readers.
Readership
The journal readership includes pharmacologists, pharmacognosist, medicinal chemists, molecular and cell biologists, immunologists, microbiologists, biochemists, biotechnologists and other related scholars. IJPT readers not only include academics but also a range of professionals including practicing professionals and medical companies and industries.
Peer Review Process
Editor-in-Chief makes an initial appraisal of each manuscript and if the topic and content seem potentially appropriate for the journal, the manuscript is assigned to a Section Editor who is a specialist on that topic. If the papers are not desk rejected, they are typically sent out to expert referees to be thoroughly reviewed. There are three main reasons for a paper to be ‘desk rejected’;
- Papers that are out of the journal scope will be desk rejected even if such papers are good.
- Papers that are in IJPT scope but do not meet the quality standards, like; novelty, intellectual depth, rigorous, and accepted language, style, or grammar, are also likely to be desk rejected.
- Papers that report human or animal studies must state the corresponding research project code of ethics to commit that the appropriate ethical standards are being considered. Otherwise, the paper will be desk rejected, even if it is good and do address the journal scope.
IJPT has a "double blind" review process and the authors and the referees are not told who wrote or reviewed the papers. The section editors need at least two authoritative reviews for making a decision as to whether to accept, reject or ask for a minor/major revision of the reviewed manuscript. The overall recommendations that will be taken to account by the Editors include;
- Accept
- Minor Revisions
- Major Revisions
- Reject
The final decision is made by the Editor-in-Chief. No more than one major revision is allowed and the revised manuscript must be submitted in less than 3 months. Also, minor revisions must not take more than 2 weeks. The revisions that are not submitted during the expected periods will be eliminated and are considered as new submissions. The peer review flowchart is presented in For Reviewers section.
Publication Charges
Iranian Journal of pharmacology and Therapeutics does NOT charge authors and readers any fee for reviewing, publishing or reading articles.
Publication Frequency
In January 2017, the publishing models of Iranian Journal of pharmacology and Therapeutics (IJPT) have moved to a continuous publication model rather than publishing conventional complete online issues every six months. Special feature issues are published separately throughout the year. The overall number of articles that is published by IJPT will probably increase from 2019 and the queue time of articles waiting to be published will decrease significantly. Also, number of layout changes, including “Cite this article as”, “Conflicts of Interest” and “Funding” sections, are made in the PDFs.
Post Publication Process
We highly encourage the authors to introduce and distribute their published achievements and articles in a form of PDF, slide shows, pod casts and movie on their personal websites, Linked in, Research gate, YouTube, and other similar sites.
Publication Ethics
Iranian Journal of Pharmacology and Therapeutics expect all parties, including the authors, the journal editors, the peer reviewers and the publisher, involved during the publishing process to strictly consider ethical behavior. Authors are expected to be aware of and comply publication ethics with regard to authorship like avoidance of ghost or guest authorship, dual submission, plagiarism, manipulation of figures, competing interests and compliance with policies on research ethics. Reviewers and Editors are required to treat manuscripts fairly and in confidence and should treat any received manuscript as a confidential document.
Open Access Policy
This journal provides immediate open access that makes the research freely available to the public allows authors reach a wider audience and foster the global and social impact of their contributions in a short time.
Funding
Iranian Journal of pharmacology and Therapeutics (IJPT) is funded and financially supported by Iran University of Medical Sciences.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
